Intrathecal Stem Cell Infusion for Spinal Cord Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current autologous stem cell therapies for spinal cord injuries lack standardization and effectiveness, with variable techniques and volumes leading to inconsistent clinical outcomes, particularly in severe cervical injuries where prompt treatment is often delayed due to limited access in underdeveloped countries, resulting in poor functional recovery.
Innovation Solution
The technique involves using sagittal MR images to guide the extent of autologous bone marrow stem cell infusion directly over the spinal cord during posterior fusion surgery, employing large volumes of bone marrow aspirate to yield a concentrate containing heterogeneous stem cells and soluble factors, which are applied both under and over the dura to directly address spinal cord damage, facilitated by a posterior approach and the use of GELFOAM as a cell delivery vehicle.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large volumes of bone marrow aspirate are used to yield heterogeneous stem cell concentrate, then therapeutic effectiveness is improved, but procedural complexity and resource requirements increase
Solution Approach 1:
The patent changes the volume parameter of bone marrow aspirate from conventional small volumes to large volumes (240cc or more), which fundamentally alters the therapeutic effectiveness. This parameter change enables the formation of sufficient heterogeneous stem cell concentrate to achieve reliable functional improvement in severe cervical SCI patients.
Solution Approach 2:
The bone marrow aspirate is segmented into distinct layers through centrifugation: red blood cell layer, bone marrow concentrate layer, and plasma layer. This segmentation allows selective use of the heterogeneous stem cell concentrate containing multipotent stem cells, platelets, and growth factors while separating unnecessary components.
2Loss of time
If direct intrathecal infusion is performed during posterior fusion surgery, then treatment timing is optimized, but surgical complexity increases
Solution Approach 1:
The patent merges the stem cell infusion procedure with the posterior fusion surgery. The heterogeneous stem cell concentrate is infused directly into the spinal canal during the same surgical session as the posterior fusion, combining two procedures into one to optimize treatment timing and reduce overall treatment time.
Solution Approach 2:
A flexible catheter is used as an intermediary device to deliver the heterogeneous stem cell concentrate directly to the spinal cord through the dural incision. This catheter enables precise intrathecal infusion while maintaining surgical accessibility and control.
3Area of stationary object
If heterogeneous stem cell concentrate is applied under and over the dura, then coverage of injured spinal cord is improved, but material consumption increases
Solution Approach 1:
The heterogeneous stem cell concentrate is applied locally to the injured spinal cord area through direct intrathecal infusion during posterior fusion surgery. The concentrate is delivered precisely to the site of injury under the dura, ensuring high local concentration and effective coverage without unnecessary dispersion to other areas.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves rapid and significant functional improvement in patients with severe cervical spinal cord injuries, even with delayed treatment, by promoting tissue regeneration and reducing secondary injury cascades, as demonstrated in two case studies with remarkable recovery in patients lacking access to advanced care.
Implementation Method 1
The bone marrow aspirate undergoes a centrifugation process after yielding three distinct layers: the deeper red blood cell layer, the bone marrow concentrates (buffy coat containing some platelets) and the superficial plasma layer containing an abundance of platelets, exosomes and soluble protein factors.
Implementation Method 2
In vitro evidence suggests that cell therapy may provide healing to the injured spinal cord by generating neural or myelin producing cells.
Implementation Method 3
The concentrated, superficial plasma (approximately 30cc) is then split evenly and applied over the GELFOAM and muscle layer after the muscle is sutured.
Data Source
AI summary
A method of treating spinal cord injuries in a patient using sagittal MR images of the spinal cord injury to guide the extent of exposure of the neuro/orthopedic surgeon during a posterior spinal fusion for the purpose of autologous stem cell therapy in the setting of spinal injury; the method using large volumes of the patient's bone marrow aspirated to yield a large quantity of heterogeneous autologous stem cell concentrate containing cellular and subcellular fractions, in addition to soluble protein factors (defined as heterogeneous concentrate) exhibiting regenerative potential which is then applied directly over the spinal cord (under the dura/arachnoid) in the areas affected.